Table 1 Patient demographics of 777 patients evaluated.

From: Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

 

BPH/LUTS

PCa

Mean

±

SD

Mean

±

SD

Age

64.6

±

8.5

61.9

±

8

PSA

6.7

±

4.7

6.5

±

5.9

Prostate volume

61.4

±

27.3

42.3

±

26.4

Gleason

5–7

    

404

 

8–10

    

39

 
 

n

% Total

n

% Total

Race

Caucasian-American

191

64%

281

59%

African-American

48

16%

139

29%

Other

61

20%

57

12%

Clinical site

CPDR/Walter Reed

119

40%

239

50%

Veteran Affairs

58

19%

34

7%

UHN

118

39%

78

16%

CCF

5

2%

126

26%

Total

300

 

477

 
  1. Age (years), PSA levels (ng/mL), and prostate volume (mL) (Mean ± standard deviation, SD). Distribution of patients by race and sampling distribution of patients from various clinical sites.
Back to article page